Skip to content

The Effect of Casein Phosphopeptide Amorphous Calcium Phosphate on Affected Dentine

The Reparative Effect of Casein Phosphopeptide Amorphous Calcium Phosphate Varnish on Caries Affected Dentine in Primary Teeth (Randomized Controlled Clinical Trial)

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04303767
Enrollment
132
Registered
2020-03-11
Start date
2020-03-01
Completion date
2021-02-01
Last updated
2020-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Caries,Dental

Keywords

Casein Phosphopeptide Amorphous Calcium Phosphate, CPP-ACP, caries affected dentine, dentine repair, Atraumatic Restorative Treatment

Brief summary

Teeth selected for intervention with Atraumatic Restorative Treatment will receive Glass Ionomer restorations (control) or MI varnish (test) before receiving the Glass Ionomer restoration

Detailed description

Patients selected to participate in the study will be randomly assigned into 2 groups. Group 1 (test): who will receive casein Phosphopeptide Amorphous Calcium Phosphate (CPP-ACP) + ART in the teeth selected, excavating only the caries infected dentine and preserving the caries affected dentine. Group 2 (control): Who will receive ART only in the teeth selected, excavating only the caries infected dentine and preserving the caries affected dentine.

Interventions

varnish containing calcium and phospate ions which act as a source for tooth remineralization

excavation of dental caries and restoring with light cured Glass Ionomer Restoration

Sponsors

Hams Hamed Abdelrahman
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
6 Years to 11 Years
Healthy volunteers
Yes

Inclusion criteria

1. Healthy patients. 2. Patients with an age range of 6-8 years old for clinical evaluation. 3. Patients ranking definitely positive or positive on Frankl scale. 4. Patients having at least 1 symptomless primary molar with caries extending to the dentine (International Caries Detection and Assessment System (ICDAS II) code 4, 5 & 6). 5. The presence of the permanent successors when examined by periapical X-ray. 6. Patients who will agree to participate in the study. For the ex-vivo sample 1. Patients with an age range of 9-11 years old. 2. The selected teeth should have more than half of their roots physiologically resorbed when examined by periapical X-ray.

Exclusion criteria

1. Patients with special health care needs (physical, mental or medical). 2. Primary molars that are mobile, ankylosed or have periapical pathology on initial examination clinically and radiographically.

Design outcomes

Primary

MeasureTime frameDescription
Evaluate the reparative ability of Casein Phosphopeptide Amorphous Calcium Phosphate varnish on caries affected dentine in primary molars.12 monthsthis is by evaluating the clinical and radiographic data and also by descriptive histological assessment

Other

MeasureTime frameDescription
Evaluate and compare the clinical outcome of Atraumatic Restorative Treatment with and without Casein Phosphopeptide Amorphous Calcium Phosphate varnish placed on caries affected dentine in primary molars to evaluate the restoration success or failure.12 monthsclinical criteria and ART success criteria will be assessed
Assess the radiographic success of Atraumatic Restorative Treatment with and without CPP-ACP varnish placed on caries affected dentine in primary molars by measuring the grey value radiographically using Image J software.12 monthsradiographic success of the teeth and radiographic density measures will be assessed
Assess histologically the quality of the formed dentine using the Polarized Light Microscope and Scanning Electron Microscope.throughout the 12 monthspolarized light microscope and scanning electron microscope will be used to describe the repaired dentine and the bacterial load

Countries

Egypt

Contacts

Primary ContactMohamed A. Bayoumi, MSc
mohamed.bayoumi@pua.edu.eg0122273853

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026